vspВопросы современной педиатрииCurrent Pediatrics1682-55271682-5535Издательство «ПедиатрЪ»10.15690/vsp.v18i4.2045vsp-2203Research ArticleОБМЕН ОПЫТОМEXCHANGE OF EXPERIENCEПробиотики в педиатрии: как подойти к выбору эффективного и безопасного препарата для детейProbiotics in Pediatrics: How to Choose Effective and Safety Specimen for a Childhttps://orcid.org/0000-0002-0535-2916ДроздовВ. Н.DrozdovVladimir N.

Дроздов Владимир Николаевич - доктор медицинских наук, профессор кафедры клинической фармакологии и пропедевтики внутренних болезней.

119991, Москва, ул. Трубецкая, д. 8

vndrozdov@yandex.ruhttps://orcid.org/0000-0001-9292-4769ВоробьёваО. А.Vorob'evaOlga A.https://orcid.org/0000-0002-7430-3341АстаповскийА. А.AstapovskyAleksandr A.https://orcid.org/0000-0001-6589-7654ШихЕ. В.ShikhEvgeniya V.Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical University (Sechenov University)Russian Federation201926112019184277284Copyright © Дроздов В.Н., Воробьёва О.А., Астаповский А.А., Ших Е.В., 20192019Дроздов В.Н., Воробьёва О.А., Астаповский А.А., Ших Е.В.Drozdov V.N., Vorob'eva O.A., Astapovsky A.A., Shikh E.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://vsp.spr-journal.ru/jour/article/view/2203

Проблема выбора пробиотика остается актуальной, что обусловлено большим количеством препаратов этого класса на фармацевтическом рынке и вместе с тем недостаточной изученностью их эффектов в крупных исследованиях с участием детей. В этой связи к назначению такого рода препаратов детям необходимо подходить с особой избирательностью. В статье проанализирована эффективность наиболее изученных пробиотических штаммов, используемых в профилактических и лечебных целях. Описаны требования, предъявляемые к пробиотическим микроорганизмам, в том числе к тем из них, которые входят в состав пробиотиков для детей. Отмечено, что пробиотики зачастую имеют статус пищевой добавки (БАД). Однако сфера их применения охватывает как профилактику, так и лечение функциональных расстройств и заболеваний желудочно-кишечного тракта.

The challenge with selection of probiotic is still very topical due to the huge amount of different kinds of probiotics on pharmaceutical market and due to the lack of major studies about their effects in children. In this regard the administration of such specimens in children should be performed with special selectivity. The efficiency of the most studied probiotic bacterial strains used in prevention and treatment were analysed in this article. Requirements for probiotic microorganisms (included those used in pediatrics) were described. It is noted that probiotics are often considered as food supplement. However they are implemented in prevention and treatment of functional disorders and diseases of the gastrointestinal tract.

детипробиотикипробиотические штаммыбезопасностьэффективностьжелудочно-кишечный трактзаболеванияфункциональные расстройстваchildrenprobioticsprobiotic bacterial strainsafetyefficiencygastrointestinal tractdiseasesfunctional disordersСтатья опубликована при поддержке компании «Пфайзер Инновации»Article is published with support of Pfizer Innovations LLCReferencesGuarner F, Khan AG, Garisch J, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics october 2011. J Clin Gastroenterol. 2012;46(6):468-481. doi: 10.1097/MCG.0b013e3182549092.Guarner F, Khan AG, Garisch J, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics october 2011. J Clin Gastroenterol. 2012;46(6):468-481. doi: 10.1097/MCG.0b013e3182549092.Hill C, Guarner F, Reid G, et al. Expert consensus document. The International scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi: 10.1038/nrgastro.2014.66.Hill C, Guarner F, Reid G, et al. Expert consensus document. The International scientific association for probiotics and prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. doi: 10.1038/nrgastro.2014.66.Guarner F, Sander МЕ, Rami E, et al. World Gastroenterology Organization Global: Guidelines Probiotics and prebiotics. 2017. Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiot-ics-english.Guarner F, Sander МЕ, Rami E, et al. World Gastroenterology Organization Global: Guidelines Probiotics and prebiotics. 2017. Available from: http://www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics/probiotics-and-prebiot-ics-english.FAO/WHO. Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food London, Ontario, Canada, April 30 and May 1, 2002. Available from: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.FAO/WHO. Working Group Report on Drafting Guidelines for the Evaluation of Probiotics in Food London, Ontario, Canada, April 30 and May 1, 2002. Available from: https://www.who.int/foodsafety/fs_management/en/probiotic_guidelines.pdf.Degnan FH. The US food and drug administration and probiotics: regulatory categorization. Clin Infect Dis. 2008;46 Suppl 2: S133-136; discussion S144-151. doi: 10.1086/523324.Degnan FH. The US food and drug administration and probiotics: regulatory categorization. Clin Infect Dis. 2008;46 Suppl 2: S133-136; discussion S144-151. doi: 10.1086/523324.Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395-404. doi: 10.1111/bcp.12267.Batchelor HK, Marriott JF. Paediatric pharmacokinetics: key considerations. Br J Clin Pharmacol. 2015;79(3):395-404. doi: 10.1111/bcp.12267.Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001;73(2 Suppl):399S-405S. doi: 10.1093/ajcn/73.2.399s.Bezkorovainy A. Probiotics: determinants of survival and growth in the gut. Am J Clin Nutr. 2001;73(2 Suppl):399S-405S. doi: 10.1093/ajcn/73.2.399s.Haschke F, Weiping W, Guozai P, et al. Clinical trials prove the safety and efficacy of the probiotic strain Bifidobacterium Bb12 in follow-up formula and growing-up milks. Monatsschr Kinderheilkd. 1998;146:26-30. doi: 10.1007/pl00014763.Haschke F, Weiping W, Guozai P, et al. Clinical trials prove the safety and efficacy of the probiotic strain Bifidobacterium Bb12 in follow-up formula and growing-up milks. Monatsschr Kinderheilkd. 1998;146:26-30. doi: 10.1007/pl00014763.He F, Ouwehan AC, Hashimoto H, et al. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol Immunol. 2001;45(3):259-262. doi: 10.1111/j.1348-0421.2001.tb02615.x.He F, Ouwehan AC, Hashimoto H, et al. Adhesion of Bifidobacterium spp. to human intestinal mucus. Microbiol Immunol. 2001;45(3):259-262. doi: 10.1111/j.1348-0421.2001.tb02615.x.Lebeer S, Claes I, Tytgat HL, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012;78(1):185-193. doi: 10.1128/AEM.06192-11.Lebeer S, Claes I, Tytgat HL, et al. Functional analysis of Lactobacillus rhamnosus GG pili in relation to adhesion and immunomodulatory interactions with intestinal epithelial cells. Appl Environ Microbiol. 2012;78(1):185-193. doi: 10.1128/AEM.06192-11.Fda. gov [Internet]. Generally Recognized as Safe (GRAS). 2019. Available from: https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras.Fda. gov [Internet]. Generally Recognized as Safe (GRAS). 2019. Available from: https://www.fda.gov/food/food-ingredients-packaging/generally-recognized-safe-gras.Fda. gov [Internet]. Microorganisms & microbial-derived ingredients used in food (Partial List). 2018. Available from: https://www.fda.gov/food/generally-recognized-safe-gras/about-gras-notification-program.Fda. gov [Internet]. Microorganisms & microbial-derived ingredients used in food (Partial List). 2018. Available from: https://www.fda.gov/food/generally-recognized-safe-gras/about-gras-notification-program.Андреева И.В. Современные доказательные данные эффективности применения Lactobacillus rhamnosus GG и Bifidobacterium lactis BB-12 в педиатрической практике // Вопросы современной педиатрии. — 2011. — Т. 10. — № 1. — С. 50-57.Andreeva IV. Evidence-based data on effectiveness of Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12 in pediatric practice. Current Pediatrics. 2011;10(1):50-57. (In Russ).Efsa. europa.eu [Internet]. Scientific opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed. 2009. doi: 10.2903/j.efsa.2009.1431.Efsa. europa.eu [Internet]. Scientific opinion on the maintenance of the list of QPS microorganisms intentionally added to food or feed. 2009. doi: 10.2903/j.efsa.2009.1431.Herman L, Chemaly M, Cocconcelli PS, et al. The qualified presumption of safety assessment and its role in EFSA risk evaluations: 15 years past. FEMS Microbiol Lett. 2019;366(1). doi: 10.1093/femsle/fny260.Herman L, Chemaly M, Cocconcelli PS, et al. The qualified presumption of safety assessment and its role in EFSA risk evaluations: 15 years past. FEMS Microbiol Lett. 2019;366(1). doi: 10.1093/femsle/fny260.Терешкина О.И. Современные критерии оценки безопасности состава лекарственных препаратов // Биомедицина. — 2011. — № 3. — С. 119-124.Tereshkina OI. Sovremennye kriterii otsenki bezopasnosti sostava lekarstvennykh preparatov. Biomeditsina. 2011;(3):119-124. (In Russ).Горелов А.В., Милютина Л.Н., Усенко Д.В. Лечение острых кишечных инфекций у детей. Пособие для врачей. — М., 2003. — 48 с.Gorelov AV, Milyutina LN, Usenko DV. Lechenie ostryh kishech-nyh infekcij u detej. Posobie dlya vrachej. Moscow; 2003. 48 р. (in Russ).Бельмер С.В., Карпина Л.М. Становление кишечного микробиоценоза у детей первого года жизни и пути его коррекции // Вопросы современной педиатрии. — 2010. — Т. 9. — № 4. — С. 138-142.Bel'mer SV, Karpina LM. Formation of intestinal biocenosis in infants and the ways of its correction. Current Pediatrics. 2010;9(4):138-142. (In Russ).Favier CF, de Vos WM, Akkermans AD. Development of bacterial and bifidobacterial communities in feces of newborn babies. Anaerobe. 2003;9(5):219-229. doi: 10.1016/j.anaer-obe.2003.07.001.Favier CF, de Vos WM, Akkermans AD. Development of bacterial and bifidobacterial communities in feces of newborn babies. Anaerobe. 2003;9(5):219-229. doi: 10.1016/j.anaer-obe.2003.07.001.Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr. 2001;73(6):1147S-1151S. doi: 10.1093/ajcn/73.6.1147S.Saavedra JM. Clinical applications of probiotic agents. Am J Clin Nutr. 2001;73(6):1147S-1151S. doi: 10.1093/ajcn/73.6.1147S.Braegger C, Chmielewska A, Decsi T, et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011;52(2):238-250. doi: 10.1097/MPG.0b013e3181fb9e80.Braegger C, Chmielewska A, Decsi T, et al. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN committee on nutrition. J Pediatr Gastroenterol Nutr. 2011;52(2):238-250. doi: 10.1097/MPG.0b013e3181fb9e80.Корниенко Е.А. Современные принципы выбора пробиотиков // Детские инфекции. — 2007. — Т. 6. — № 3. — С. 63-68.Корниенко Е.А. Современные принципы выбора пробиотиков // Детские инфекции. — 2007. — Т. 6. — № 3. — С. 63-68. [Kornienko E.A. Modern principles of selecting suitable probiotics. Detskie infekcii. 2007;6(3):63-68. (In Russ).]Cruchet S, Furnes R, Maruy A, et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17(3): 199-216. doi: 10.1007/s40272-015-0124-6.Cruchet S, Furnes R, Maruy A, et al. The use of probiotics in pediatric gastroenterology: a review of the literature and recommendations by Latin-American experts. Paediatr Drugs. 2015;17(3): 199-216. doi: 10.1007/s40272-015-0124-6.Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015;61(4):273-292.Pace F, Pace M, Quartarone G. Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol Dietol. 2015;61(4):273-292.Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin North Am. 2005;34(3):483-498, ix. doi: 10.1016/j.gtc.2005.05.011.Doron S, Snydman DR, Gorbach SL. Lactobacillus GG: bacteriology and clinical applications. Gastroenterol Clin North Am. 2005;34(3):483-498, ix. doi: 10.1016/j.gtc.2005.05.011.Spinosa MR, Wallet F, Courcol RJ, Oggioni MR. The trouble in Tracing opportunistic pathogens: cholangitis due to Bacillus in a French hospital caused by a strain related to an Italian probiotic? Microb Ecol Health Dis. 2000;(12):99-101. doi: 10.1080/089106000435491.Spinosa MR, Wallet F, Courcol RJ, Oggioni MR. The trouble in Tracing opportunistic pathogens: cholangitis due to Bacillus in a French hospital caused by a strain related to an Italian probiotic? Microb Ecol Health Dis. 2000;(12):99-101. doi: 10.1080/089106000435491.Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-1017. doi: 10.1086/318130.Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis. 2000;31(4):1012-1017. doi: 10.1086/318130.Salminen S, Benno Y, de Vos W. Intestinal colonisation, microbiota and future probiotics? Asia Pac J Clin Nutr. 2006;15(4):558-562.Salminen S, Benno Y, de Vos W. Intestinal colonisation, microbiota and future probiotics? Asia Pac J Clin Nutr. 2006;15(4):558-562.Агафонова Е.А., Петренко Л.Л., Леоненко Н.И., и др. Клиническое и иммунобиологическое значение пробиотической терапии у детей // Здоровье ребенка. — 2010. — № 2. — С. 61-64.Agafonova EA, Petrenko LL, Leonenko NI, et al. Clinical and immunobiological value of probiotic therapy in children. Zdorov'ia dytyny. 2010;(2):61-64. (In Russ).Беляева И.А., Митиш М.Д., Катосова Л.К. Эффективность использования пробиотиков у недоношенных детей // РМЖ. — 2009. — Т. 17. — № 15. — С. 1000-1004.Belyaeva IA, Mitish MD, Katosova LK. Effektivnost' ispol'zovaniya probiotikov u nedonoshen-nykh detey. RMZ. 2009;17(15):1000-1004. (In Russ).Зимняков В.М., Гаврюшина И.В. Заквасочная культура — технологический инструмент высококачественных молочных продуктов // Инновационная техника и технология. — 2014. — № 4. — С. 8-12.Zimnyakov VM, Gavryushina IV. Impact on technological properties of prebiotics dairy and meat products. Innovatsionnaya tekhnika i tekhnologiya. 2014;(4):8-12. (In Russ).Тарасова Л.А., Данилова В.Н., Воронина Л.Н. Опыт коррекции нарушения баланса микробиоты кишечника у младенцев на фоне вторичной лактазной недостаточности // Педиатрическая фармакология. — 2011. — Т. 8. — № 4. — С. 122-124.Tarasova LA, Danilova VN, Voronina LN. Experience in the correction of the intestine microbiotadys dysbalance on the background of secondary lactase deficiency. Pediatric pharmacology. 2011;8(4):122-124. (In Russ).Correa NB, Peret Filho LA, Penna FJ. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus ther-mophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005;39(5):385-389. doi: 10.1097/01.mcg.0000159217.47419.5b.Correa NB, Peret Filho LA, Penna FJ. A randomized formula controlled trial of Bifidobacterium lactis and Streptococcus ther-mophilus for prevention of antibiotic-associated diarrhea in infants. J Clin Gastroenterol. 2005;39(5):385-389. doi: 10.1097/01.mcg.0000159217.47419.5b.Guandalini S, Magazzu G, Chiaro A, et al. VSL3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30. doi: 10.1097/MPG.0b013e3181ca4d95.Guandalini S, Magazzu G, Chiaro A, et al. VSL3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study. J Pediatr Gastroenterol Nutr. 2010;51(1):24-30. doi: 10.1097/MPG.0b013e3181ca4d95.Hungin AP, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms — an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47(8):1054-1070. doi: 10.1111/apt.14539.Hungin AP, Mitchell CR, Whorwell P, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms — an updated evidence-based international consensus. Aliment Pharmacol Ther. 2018;47(8):1054-1070. doi: 10.1111/apt.14539.Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice — an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864-886. doi: 10.1111/apt.12460.Hungin AP, Mulligan C, Pot B, et al. Systematic review: probiotics in the management of lower gastrointestinal symptoms in clinical practice — an evidence-based international guide. Aliment Pharmacol Ther. 2013;38(8):864-886. doi: 10.1111/apt.12460.Ducrotte P Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018. doi: 10.3748/wjg.v18.i30.4012.Ducrotte P Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol. 2012;18(30):4012-4018. doi: 10.3748/wjg.v18.i30.4012.Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344(8929):1046-1049. doi: 10.1016/s0140-6736(94)91708-6.Saavedra JM, Bauman NA, Oung I, et al. Feeding of Bifidobacterium bifidum and Streptococcus thermophilus to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet. 1994;344(8929):1046-1049. doi: 10.1016/s0140-6736(94)91708-6.Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004;79(2):261-267. doi: 10.1093/ajcn/79.2.261.Saavedra JM, Abi-Hanna A, Moore N, Yolken RH. Long-term consumption of infant formulas containing live probiotic bacteria: tolerance and safety. Am J Clin Nutr. 2004;79(2):261-267. doi: 10.1093/ajcn/79.2.261.Петров В.И. Базисные принципы и методология доказательной медицины // Вестник Волгоградского государственного медицинского университета. — 2011. — № 2. — С. 3-8.Petrov VI. Basic principles and methodology in evidence based medicine. Vestnik VolGMU. 2011;(2):3-8. (In Russ).Riezzo G, Orlando A, D'Attoma B, et al. Randomised clinical trial: effi cacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation — a double-blind, controlled, crossover study. Aliment Pharmacol Ther. 2012;35(4): 441-450. doi: 10.1111/j.1365-2036.2011.04970.x.Riezzo G, Orlando A, D'Attoma B, et al. Randomised clinical trial: effi cacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation — a double-blind, controlled, crossover study. Aliment Pharmacol Ther. 2012;35(4): 441-450. doi: 10.1111/j.1365-2036.2011.04970.x.Taipale T, Pienihakkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105(3):409-416. doi: 10.1017/S0007114510003685.Taipale T, Pienihakkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105(3):409-416. doi: 10.1017/S0007114510003685.Holscher HD, Czerkies LA, Cekola P, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr. 2012;36(1 Suppl):106S-117S. doi: 10.1177/0148607111430817.Holscher HD, Czerkies LA, Cekola P, et al. Bifidobacterium lactis Bb12 enhances intestinal antibody response in formula-fed infants: a randomized, double-blind, controlled trial. JPEN J Parenter Enteral Nutr. 2012;36(1 Suppl):106S-117S. doi: 10.1177/0148607111430817.Rizzardini G, Eskesen D, Calder PC, et al. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2012;107(6): 876-884. doi: 10.1017/S000711451100420X.Rizzardini G, Eskesen D, Calder PC, et al. Evaluation of the immune benefits of two probiotic strains Bifidobacterium animalis ssp. lactis, BB-12® and Lactobacillus paracasei ssp. paracasei, L. casei 431 in an influenza vaccination model: a randomised, double-blind, placebo-controlled study. Br J Nutr. 2012;107(6): 876-884. doi: 10.1017/S000711451100420X.Zhao M, Shen C, Ma L. Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis. Int J Dermatol. 2018;57(6):635-641. doi: 10.1111/ijd.13873Zhao M, Shen C, Ma L. Treatment efficacy of probiotics on atopic dermatitis, zooming in on infants: a systematic review and meta-analysis. Int J Dermatol. 2018;57(6):635-641. doi: 10.1111/ijd.13873

The authors declare that there are no conflicts of interest present.